What the Evidence Actually Supports Its worth being precise about the state of evidence, because the gap between preclinical research and proven human clinical outcomes is significant in this area: Strong preclinical evidence: Hundreds of cell culture and animal studies demonstrate GHK-Cus biological activity across multiple pathways Moderate clinical evidence for topical applications: Several controlled human trials support skin benefits of topical GHK-Cu formulations Limited human evidence for systemic effects: The more dramatic claims tissue regeneration, gene expression reset, anti-aging effects throughout the body are largely supported by in vitro and animal data without the controlled human trials required to confirm efficacy and safety The scientific communitys interest in GHK-Cu is well-founded
Clinicians value this product for its versatility, as it can be administered either via slow intravenous injection or diluted for infusion depending on treatment requirements
Spatial learning-induced increase in agmatine levels at hippocampal CA1 synapses
in Investigative Ophthalmology & Visual Science (2010) showed that TB-500 promotes keratinocyte migration by up to 240% compared to controls, dramatically accelerating wound closure rates
In addition to being in good general health and free of any life-threatening diseases or medical conditions that could hinder healing, good candidates are typically within 35% of their ideal body weight
KLOW 80 remains an investigational peptide with limited human clinical data